TP53 and acute myeloid leukemia: The combination of eprenetapopt with AZA/VEN demonstrated an acceptable safety profile and encouraging activity, with 64% of patients achieving an overall response and 38% of patients with TP53-mutated AML achieving CR in a phase I expansion study [134].